FDA Will Accept Behind-The-Counter NDAs While Mulling “Continuum” Class
This article was originally published in The Tan Sheet
Executive Summary
FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff
You may also be interested in...
OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley
Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say
OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley
Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say
OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley
Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say